<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01095874</url>
  </required_header>
  <id_info>
    <org_study_id>AGRAAH 08-01</org_study_id>
    <nct_id>NCT01095874</nct_id>
  </id_info>
  <brief_title>Allogeneic Hematopoietic Stem Cell Transplantation Evaluation in High Risk Myelodysplasia: an Observational Non-interventional Study</brief_title>
  <acronym>ONIalloMDS</acronym>
  <official_title>Allogeneic Hematopoietic Stem Cell Transplantation Evaluation in High Risk Myelodysplasia: an Observational Non-interventional Study Comparing Outcome of Patients Aged From 50 to 70 Years With or Without Donor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint-Louis Hospital, Paris, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Avicenne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Saint-Louis Hospital, Paris, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare outcome of high risk myelodysplasia patients aged
      from 50 to 70 years with or without HLA compatible (9 or 10 identities / 10) donor. High risk
      myelodysplasia includes IPSS intermediate 2 and high myelodysplasia and patients with sever
      thrombocytopenia. Patients are registered when they acquire risk factors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival in patient with or without donor</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">164</enrollment>
  <condition>Myelodysplasia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from 50 to 70 years with high risk myelodysplasia and eligible for transplantation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  50 to 70 years

          -  For myelodysplasia other than CMML: patients can be included if they have at least one
             of these criteria:

               1. IPSSintermediate 1 and poor cytogenetics (complex, 3 or 7 abnormality);

               2. thrombopenia &lt; 20x10ex9/L:

               3. IPSS intermediate 2 or high

          -  For CMML: patients can be included if they have at least one of these criteria:

               1. 2 of these criteria: hyperleucocytosis &gt; 10x10exp9/L, splenomegaly&gt;18cm,
                  hemoglobin &lt; 10gr/dl, platelet &lt; 100x10ex9/L

               2. IPSS intermediate 2 or high

        Exclusion Criteria:

          -  Patient not eligible for transplantation (including patients without donor)because of
             severe co-morbidity including:

          -  Renal failure with creatinine clearance &lt; 30ml/min

          -  Cirrhosis or hepatic failure

          -  Respiratory disease with vital capacity &lt; 30%

          -  Uncontrolled cardiac failure

          -  Uncontrolled neurological disease

          -  Poor performance status with karnofsky &lt; or = 60%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>HÃ´pital Saint-Louis</name>
      <address>
        <city>Paris Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2010</study_first_submitted>
  <study_first_submitted_qc>March 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2010</study_first_posted>
  <last_update_submitted>January 17, 2014</last_update_submitted>
  <last_update_submitted_qc>January 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Saint-Louis Hospital, Paris, France</investigator_affiliation>
    <investigator_full_name>Marie Robin</investigator_full_name>
    <investigator_title>Dr Marie Robin</investigator_title>
  </responsible_party>
  <keyword>myelodysplasia</keyword>
  <keyword>allogeneic hematopoietic stem cell transplantation</keyword>
  <keyword>Survival</keyword>
  <keyword>Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

